logo
Wells Fargo Invests $1 Million Toward Rural Small Businesses in South Dakota

Wells Fargo Invests $1 Million Toward Rural Small Businesses in South Dakota

MOBRIDGE, S.D., August 20, 2025 /3BL/ - The Wells Fargo Foundation recently announced a $1 million philanthropic investment to support small business growth across South Dakota, with a focus on empowering entrepreneurs in rural and tribal communities. The funding will be distributed evenly between Akiptan, a Native-led community development financial institution, and GROW South Dakota (GROW SD), a statewide economic development organization, providing critical resources and capital to small business owners and agricultural producers throughout the state.
As Senate Majority Leader John Thune (R-S.D.) highlighted at the announcement in Mobridge, investing in rural small businesses means investing in the future of South Dakota: 'Small businesses are an essential part of the fabric of our communities and our way of life in South Dakota. They provide good-paying jobs and opportunities for so many hardworking folks across our state. This investment will go a long way in helping them grow and create new jobs, especially in rural and tribal communities.'
Jason Rosenberg, head of Public Affairs for Wells Fargo, emphasized the bank's history in South Dakota at the event and the importance of community investment: 'Wells Fargo is proud to support small businesses by expanding avenues to capital as they create economic growth and bring jobs to towns throughout the state and the country. With this new funding, Akiptan and GROW SD can help more small businesses thrive in rural and tribal communities across South Dakota.'
Akiptan expands opportunities for agricultural producers
Akiptan's mission is to transform Native agriculture and food economies by delivering creative capital, leading paradigm changes, and enhancing producer prosperity across Indian Country. Since lending operations began in 2019, Akiptan has addressed the gap in access to capital by offering patient, non-extractive lending tailored for producers across Indian country. For Akiptan, each agricultural operation is more than just a business - it's a family legacy and a way of life.
'We are excited and humbled to receive these funds from Wells Fargo,' said Skya Ducheneaux, Executive Director, Akiptan. 'We can't wait to put these dollars to work in Indian Country by supporting agriculture operations. Especially in South Dakota, agriculture is a root-level driving force of the economy that we are proud to support.'
GROW SD supports rural small business success
GROW SD will directly support rural economic development by expanding access to capital and by providing business support for small business owners, enabling business growth and the preservation or creation of jobs. All participating businesses will also benefit from customized technical assistance, including one-on-one advising and targeted training in areas such as cash flow forecasting, credit counseling, and marketing.
'Access to capital remains one of the greatest challenges in our rural communities, and this collaboration allows us to deliver the critical funding and assistance that local entrepreneurs need to grow and succeed,' said Marcia Erickson, GROW SD Co-CEO. 'It is also a privilege to work alongside Akiptan in this partnership and to support its efforts in serving farm producers.'
'This $1 million investment into South Dakota from Wells Fargo will strengthen local economies and create a lasting impact across the communities we serve. We are grateful to be able to expand the reach of our work across rural communities,' Lori Finnesand, Co-CEO, added.
For more information, small business owners can visit www.akitpan.org or www.growsd.org.
###
Media Contacts:
Maureen Nelson, GROW South Dakota, [email protected]
Dawn LeBeau, Akiptan, [email protected]
Kim Erlichson, Wells Fargo, [email protected]
Visit 3BL Media to see more multimedia and stories from Wells Fargo & Company
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

West Loop Strategy Signs Strategic Collaboration Agreement with AWS to Accelerate Adoption of Generative A.I. and Modernize Business Intelligence
West Loop Strategy Signs Strategic Collaboration Agreement with AWS to Accelerate Adoption of Generative A.I. and Modernize Business Intelligence

Business Wire

time18 minutes ago

  • Business Wire

West Loop Strategy Signs Strategic Collaboration Agreement with AWS to Accelerate Adoption of Generative A.I. and Modernize Business Intelligence

CHICAGO--(BUSINESS WIRE)--West Loop Strategy, an Advanced Tier AWS Partner and recognized leader in cloud analytics consulting, has signed a Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS). This partnership aims to accelerate adoption of Generative A.I., Amazon Q and Amazon QuickSight, while helping organizations modernize legacy business intelligence (B.I.) platforms and unlock scalable insights across AWS services. "Our exceptional team combines cutting-edge Artificial Intelligence with good old-fashioned 'Natural Intelligence' to drive successful adoption during this pivotal time in technology innovation. " - Kevin Cummings, co-founder of West Loop Strategy Share 'I am excited and proud. This agreement underscores our continued investment and commitment to helping customers simplify and scale analytics and Generative A.I. adoption,' said Kevin Cummings, co-founder of West Loop Strategy. 'We've guided organizations in reducing complexity, consolidating their technology footprint, and unlocking business value through AWS's Generative A.I. solutions. Our exceptional team combines cutting-edge Artificial Intelligence with good old-fashioned 'Natural Intelligence' to drive successful adoption during this pivotal time in technology innovation. A special thank-you to our partners at AWS, who work hand-in-hand with us and our customers to ensure A.I. is used responsibly and aligned to realistic, impactful outcomes.' Building on a shared commitment to generative A.I. innovation, West Loop Strategy and AWS will continue to invest in technical enablement and go-to-market alignment around Amazon Q, OpenSearch, Bedrock, Amazon QuickSight, and generative B.I. solutions. This collaboration is designed to help customers accelerate cloud-native adoption, modernize legacy B.I. platforms, and deliver intelligent, secure A.I. experiences at scale. Through this agreement, West Loop Strategy and AWS will empower organizations to: Leverage Generative B.I. capabilities through Amazon QuickSight Q to enable natural language querying and faster, self-service insights. Accelerate B.I. modernization by migrating dashboards and models from legacy business intelligence tools to Amazon QuickSight. Utilize OpenSearch to build scalable, customizable search and analytics solutions that complement B.I. modernization efforts. Enable governed self-service analytics at scale by combining QuickSight's row-level security with AWS-native infrastructure. Deliver secure, compliant analytics solutions for customers in highly regulated industries, including healthcare, financial services, and the public sector. The SCA builds on a long-standing collaboration between AWS and West Loop Strategy. With over 300 successful A.I. analytics and B.I. projects delivered, West Loop Strategy brings deep expertise in migrating and evolving dashboards and data models from legacy platforms to AWS-native tools. Their QuickSight Migration Accelerator helps organizations reduce complexity and eliminate licensing overhead from legacy B.I. systems. Loop, West Loop Strategy's custom-branded QuickSight-embedded portal, enables teams to deliver real-time insights across departments. Paired with generative B.I. capabilities in QuickSight Q, customers can ask questions in natural language, uncover insights faster, and make smarter, data-driven decisions with ease. Through its partnership with AWS, West Loop Strategy helps Fortune 100 financial services companies modernize their analytics with Amazon QuickSight's Generative A.I., unlocking value through modern user experiences. A top-tier financial institution turned to this partnership to migrate from legacy B.I. tools, improve dashboard responsiveness, and reduce query complexity. This cut load times, streamlined data workflows, and expanded access to advanced analytics. West Loop Strategy's custom QuickSight Migration Accelerator has empowered teams to reduce licensing costs and increase user adoption. Customers now benefit from scalable data visualizations, governed access, and intuitive natural language querying powered by QuickSight Q. 'Bringing A.I. into the traditional business intelligence space represents a transformative shift in the way that organizations and users interact with B.I. - if implemented correctly, organizations can democratize B.I. by putting these new tools like Q directly in the hands of business users. I think we are witnessing the rise of the 'citizen developer' and our approach with enterprise customers is to help empower and enable them,' said Alex Gottemoller, CFA, co-founder of West Loop Strategy. 'Our POC-to-migration approach allows us to accurately assess where each customer is in their journey, balancing discovery with delivery. We align technical capabilities closely with business needs, while fostering the organizational support essential for long-term success.' About West Loop Strategy Founded in 2019, West Loop Strategy is a Chicago-based consultancy helping organizations modernize their A.I. and analytics stacks through Amazon QuickSight, Bedrock, OpenSearch and other AWS services. As a trusted AWS Advanced Tier Partner and QuickSight Service Delivery Partner, West Loop Strategy delivers scalable, serverless business intelligence solutions tailored to the needs of modern enterprises. Learn more at

PROCEPT BioRobotics (PRCT) Outlook Adjusted as System Replacement Forecasts Shift
PROCEPT BioRobotics (PRCT) Outlook Adjusted as System Replacement Forecasts Shift

Yahoo

timean hour ago

  • Yahoo

PROCEPT BioRobotics (PRCT) Outlook Adjusted as System Replacement Forecasts Shift

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) ranks among the . On August 7, Wells Fargo maintained its Overweight rating on PROCEPT BioRobotics Corporation (NASDAQ:PRCT) but reduced its price target from $75 to $58. The change follows management's announcement that it no longer anticipates any system replacements in the second half of 2025, reversing earlier projections of roughly 10 replacements this year. Given that the majority of its installed base is only three years old, Wells Fargo pointed out that PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has overstated the need for replacements, even though the company forecasts system life to be five to seven years. The firm currently projects 10 replacements at an average selling price of $350,000 for 2026 and expects PROCEPT BioRobotics Corporation (NASDAQ:PRCT) management to discuss its replacements and trade-in strategy when delivering guidance for the upcoming year. PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is a commercial-stage company that focuses on urology surgical robotics systems. The company's flagship product, the AquaBeam Robotic System, is a cutting-edge image-guided device intended for minimally invasive urologic procedures. While we acknowledge the potential of PRCT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PRCT and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Verantos to Present Practical Approaches in High-Validity Real-World Evidence Generation at ISPE's 41st Annual Meeting
Verantos to Present Practical Approaches in High-Validity Real-World Evidence Generation at ISPE's 41st Annual Meeting

Business Wire

timean hour ago

  • Business Wire

Verantos to Present Practical Approaches in High-Validity Real-World Evidence Generation at ISPE's 41st Annual Meeting

MENLO PARK, Calif.--(BUSINESS WIRE)-- Verantos, the global leader in high-validity real-world evidence at scale, announced today that it will present practical approaches for generating high-validity real-world evidence (RWE) at the International Society for Pharmacoepidemiology (ISPE) 41st Annual Meeting in Washington, D.C. The goal isn't just to measure data reliability; it's to optimize it and to do so using peer-reviewed, published methods so metrics can't be gamed. Share CEO Dan Riskin will share approaches to achieve fit-for-use RWD based on real-world learnings from large pharma collaborations and the FDA-sponsored Verantos-led TRUST and VERIFY studies. He will discuss 'Data reliability: implementing accuracy, completeness, and traceability in practice.' 'The goal isn't just to measure data reliability; it's to optimize it and to do so using peer-reviewed, published methods so metrics can't be gamed,' said Riskin. 'Evidence generated using low-quality or untested RWD remains suspect as it always has been.' Symposium snapshot ISPE 41st Annual Meeting, Washington, D.C. Real-world evidence fit for regulatory applications — what does good look like? Tuesday, August 26, 10:30am EDT Verantos will detail practical implementation approaches to quantify and improve accuracy, completeness, and traceability consistent with peer-reviewed methods and learnings from the TRUST and VERIFY studies. Early findings from this work have been published in JAMA Network Open, providing a transparent foundation for reliability measurement and optimization. About Verantos Verantos is the global leader in high-validity real-world evidence for life sciences organizations. By incorporating robust clinical narrative data and artificial intelligence technology, Verantos is the first company to generate high-validity evidence at scale across therapeutic areas with measured accuracy, completeness, and traceability. Credible evidence accelerates clinical development, market access, medical affairs, pharmacovigilance, and regulatory initiatives.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store